Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H2 2019, provides an overview of the Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline landscape.
H1N1 Infection also called as swine flu is a new kind of flu in humans. It's caused by a contagious virus. H1N1 flu infects the breathing tubes in nose, throat, and lungs. The disease is contagious. When people who have it cough or sneeze, they spray tiny drops of the virus into the air. Signs and symptoms include cough, fever, sore throat, stuffy or runny nose, body aches, headache and fatigue. Treatment includes medication (antiviral drugs).
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H1N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 7, 10, 4, 44, 7 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 4, 2, 13 and 2 molecules, respectively.
Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H1N1 Subtype Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Influenza A Virus, H1N1 Subtype Infections - Overview
Influenza A Virus, H1N1 Subtype Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Influenza A Virus, H1N1 Subtype Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Influenza A Virus, H1N1 Subtype Infections - Companies Involved in Therapeutics Development
AbbVie Inc
Abzyme Therapeutics LLC
Adimmune Corp
Akshaya Bio Inc
Alla Chem LLC
Allergy Therapeutics Plc
Altimmune Inc
Ansun Biopharma Inc
Asavi Llc
AstraZeneca Plc
Beijing Minhai Biotechnology Co Ltd
BlueWillow Biologics Inc
Brandenburg Antiinfektiva GmbH
BunyaVax BV
CEL-SCI Corp
Changchun Bcht Biotechnology Co Ltd
Chicago Biosolutions Inc
CHO Pharma Inc
Cidara Therapeutics Inc
Cilian AG
Cocrystal Pharma Inc
Curevac AG
Cytocom Inc
Dnarx LLC
Emergent BioSolutions Inc
Ena Therapeutics Pty Ltd
EpiVax Inc
Etubics Corp
FluGen Inc
Gamma Vaccines Pty Ltd
Genentech Inc
GlaxoSmithKline Plc
Greffex Inc
i2 Pharmaceuticals Inc
ILiAD Biotechnologies LLC
Imutex Ltd
InvVax Inc
Jiangsu Kanion Pharmaceutical Co Ltd
Johnson & Johnson
Kineta Inc
Mayly Life Sciences
Medicago Inc
Microbiotix Inc
NanoViricides Inc
New Amsterdam Sciences Inc
Novavax Inc
OPKO Health Inc
PeptiDream Inc
Recce Ltd
Sanofi Pasteur SA
Sciogen Inc
Seqirus Ltd
Serum Institute of India Ltd
TechnoVax Inc
Tiba Biotech LLC
Touchlight Genetics Ltd
UMN Pharma Inc
Vaccibody AS
Vacthera BioTech GmbH
Vaxart Inc
Vaxxas Pty Ltd
Viramatix Sdn Bhd
Virion Biotherapeutics
Vironova Medical AB
Virvio Inc
Visterra Inc
Vivaldi Biosciences Inc
Influenza A Virus, H1N1 Subtype Infections - Drug Profiles
(oseltamivir phosphate + pimodivir hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
A-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Afluria Quadrivalent - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aspidasept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-5027 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-5080 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
B-1201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CB-012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CC-42344 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CHOS-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CiFlu - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CV-7302 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DAS-181 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
diridavumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ETBX-051 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Flu-v - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fluad (Quadrivalent) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fludase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fluzone QIV HD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein for Viral Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gamma-Flu - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GHB-11L1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GREFLU/CAL - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
H1N1 [A/Aichi/2/68] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HB-36.6 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
infectious disease vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H1N1] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/Michigan/45/2015 (H1N1)] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/Puerto Rico/8/1934 [H1N1]] (monovalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain H1N1] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B/ Yamagata + B/ Victoria] (quadrivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, split virion) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1+A/H3N2+B] (trivalent, split virion) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1] (split virion) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H5N1 + A/H1N1] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KIN-1148 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LEAPS-H1N1-DC - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MBX-2546 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MC-08 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MDG-2271 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
metenkefalin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit Hemagglutinin for Influenza Virus A Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit Neuraminidase for Influenza A Virus H1N1 and H5N1 Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAS-911 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nasovax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NB-1008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NP-025 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nucleozin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NVINF-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NVINF-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotides for Influenza A Virus H1N1 Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PD-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides for Influenza Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pertussis [strain BPZE1] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pimodivir hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RECCE-327 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Target Sialic Acid Receptor for Influenza A Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REDEE FLU - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Neuraminidase for Influenza A Virus, H1N1 Subtype Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Influenza A Virus H1N1 and H5N1 Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for RSV and Influenza A Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Block M2 Channel for Influenza A Virus, H1N1 Subtype Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Neuraminidase for Influenza A Virus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PB2 for Influenza A Virus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Influenza, HSV and HIV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Staphylococcus Aureus Infections and H1N1 Influenza - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TVX-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UMN-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VH-244 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VIS-410 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VMTX-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VNFC-045 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VNFC-051 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VTH-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VXAA-1.1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WLBU-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Influenza A Virus, H1N1 Subtype Infections - Dormant Projects
Influenza A Virus, H1N1 Subtype Infections - Discontinued Products
Influenza A Virus, H1N1 Subtype Infections - Product Development Milestones
Featured News & Press Releases
Nov 04, 2019: Sanofi: FDA approves Fluzone High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older
Oct 16, 2019: Novavax begins Phase III clinical trial for influenza vaccine NanoFlu
Jun 27, 2019: Novavax confirms accelerated approval pathway available for licensure of Nanoflu
Apr 11, 2019: Altimmune to present NasoVAX Phase 2 data at the World Vaccine Congress in Washington, D.C.
Mar 29, 2019: hVIVO and Imutex to present at the Influenza Vaccines for the World (IVW 2019) conference at the Royal College of Physicians of Edinburgh, Scotland
Jan 10, 2019: HVIVO reports that the Phase IIb viral challenge Study for FLU-v (FLU-v004) achieved the primary endpoint of a statistically significant reduction in mild to moderate influenza
Jan 03, 2019: Novavax announces positive phase 2 NanoFlu results in older adults
Nov 28, 2018: Vaxart to present at World Vaccine and Immunotherapy Congress West Coast 2018
Nov 05, 2018: UNC researchers develop platform for universal Flu Vaccine
Sep 27, 2018: Novavax starts Phase ll trial of NanoFlu for seasonal influenza
Sep 25, 2018: AstraZeneca ships FLUMIST QUADRIVALENT vaccine in the US for 2018-2019 flu season
Sep 17, 2018: Virion Appoints Vanessa King as President & CEO and Isabel Najera as CSO
Sep 04, 2018: Altimmune announces additional positive data from its phase 2a study of NasoVAX Intranasal Influenza Vaccine
Jun 18, 2018: hVIVO reports positive results from the Phase IIb field study of FLU-v (FLU-v 003) representing a significant advance in the management of influenza disease
Apr 04, 2018: Vivaldi Biosciences Presents Data at the World Vaccine Congress Demonstrating Potential of deltaFLU as Universal Influenza Vaccine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 5: Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Table 6: Number of Products under Development by Universities/Institutes, H2 2019
Table 7: Products under Development by Companies, H2 2019
Table 8: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 9: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 10: Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Table 11: Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Table 12: Products under Development by Universities/Institutes, H2 2019
Table 13: Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Table 14: Number of Products by Stage and Target, H2 2019
Table 15: Number of Products by Stage and Mechanism of Action, H2 2019
Table 16: Number of Products by Stage and Route of Administration, H2 2019
Table 17: Number of Products by Stage and Molecule Type, H2 2019
Table 18: Influenza A Virus, H1N1 Subtype Infections - Pipeline by AbbVie Inc, H2 2019
Table 19: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Abzyme Therapeutics LLC, H2 2019
Table 20: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Adimmune Corp, H2 2019
Table 21: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Akshaya Bio Inc, H2 2019
Table 22: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Alla Chem LLC, H2 2019
Table 23: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Allergy Therapeutics Plc, H2 2019
Table 24: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Altimmune Inc, H2 2019
Table 25: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Ansun Biopharma Inc, H2 2019
Table 26: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Asavi Llc, H2 2019
Table 27: Influenza A Virus, H1N1 Subtype Infections - Pipeline by AstraZeneca Plc, H2 2019
Table 28: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2019
Table 29: Influenza A Virus, H1N1 Subtype Infections - Pipeline by BlueWillow Biologics Inc, H2 2019
Table 30: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Brandenburg Antiinfektiva GmbH, H2 2019
Table 31: Influenza A Virus, H1N1 Subtype Infections - Pipeline by BunyaVax BV, H2 2019
Table 32: Influenza A Virus, H1N1 Subtype Infections - Pipeline by CEL-SCI Corp, H2 2019
Table 33: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Changchun Bcht Biotechnology Co Ltd, H2 2019
Table 34: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Chicago Biosolutions Inc, H2 2019
Table 35: Influenza A Virus, H1N1 Subtype Infections - Pipeline by CHO Pharma Inc, H2 2019
Table 36: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Cidara Therapeutics Inc, H2 2019
Table 37: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Cilian AG, H2 2019
Table 38: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Cocrystal Pharma Inc, H2 2019
Table 39: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Curevac AG, H2 2019
Table 40: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Cytocom Inc, H2 2019
Table 41: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Dnarx LLC, H2 2019
Table 42: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Emergent BioSolutions Inc, H2 2019
Table 43: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Ena Therapeutics Pty Ltd, H2 2019
Table 44: Influenza A Virus, H1N1 Subtype Infections - Pipeline by EpiVax Inc, H2 2019
Table 45: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Etubics Corp, H2 2019
Table 46: Influenza A Virus, H1N1 Subtype Infections - Pipeline by FluGen Inc, H2 2019
Table 47: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Gamma Vaccines Pty Ltd, H2 2019
Table 48: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Genentech Inc, H2 2019
Table 49: Influenza A Virus, H1N1 Subtype Infections - Pipeline by GlaxoSmithKline Plc, H2 2019
Table 50: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Greffex Inc, H2 2019
Table 51: Influenza A Virus, H1N1 Subtype Infections - Pipeline by i2 Pharmaceuticals Inc, H2 2019
Table 52: Influenza A Virus, H1N1 Subtype Infections - Pipeline by ILiAD Biotechnologies LLC, H2 2019
Table 53: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Imutex Ltd, H2 2019
Table 54: Influenza A Virus, H1N1 Subtype Infections - Pipeline by InvVax Inc, H2 2019
Table 55: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2019
Table 56: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Johnson & Johnson, H2 2019
Table 57: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Kineta Inc, H2 2019
Table 58: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Mayly Life Sciences, H2 2019
Table 59: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Medicago Inc, H2 2019
Table 60: Influenza A Virus, H1N1 Subtype Infections - Pipeline by Microbiotix Inc, H2 2019
List of Figures
Figure 1: Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Top 10 Targets, H2 2019
Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Figure 10: Number of Products by Top 10 Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019
